RxCelerate has considerable expertise in optimising and enabling the synthesis of material for both preclinical toxicity studies, but also for the clinic.

Our preferred model is to optimise the synthesis in house and then to manage other providers to prepare bulk material to GMP as required.

We can also manage formulation development and IMPD preparation on behalf of the client.